Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Question-and-Answer SessionSo obviously, a lot going on at J&J. Maybe starting off with icotrokinra. So obviously, we know that there is a submission to regulators. How should we kind of think about next steps? When could we see approval? And have you guys started preparing for launch as of today?David LeeGlobal Therapeutic Area Head, Immunology for Janssen Pharmaceutical Sure. Well, I maybe will start. Let's start with icotrokinra. It's the first targeted oral peptide to the -- highly selective to the IL-2 ...